Abstract
Physicians prescribing drugs are routinely confronted with the balance between efficacy and toxicity. Pharmacogenetics involves the study of how inheritance influences response to drugs, and its goal is to enable the appropriate selection of these individuals, thus eliminating unpredictable responses. Pharmacogenetics can be used to identify target populations that either will have minimal benefit or a better outcome including better survival or improvement in surrogate end points. As we move towards common use of targeted therapies, the future of medicine will involve an examination of the interplay between multiple genetic factors, as the response to drugs is likely to be complex and polyfactorial especially in chronic diseases. There has already been some success in situations where single genes play a large role in the overall drug response, and this is discussed with reference to commonly used cytotoxics and antiretrovirals, encompassing the major principles of pharmacogenetics.
Keywords: Cancer, HIV, pharmacogenetics, chemotherapy, polymorphisms
Current Drug Safety
Title: Host Pharmacogenetics in the Treatment of HIV and Cancer
Volume: 1 Issue: 1
Author(s): Alan Winston, Eleftheria Hatzimichael, Vanessa Marvin, Justin Stebbing and Mark Bower
Affiliation:
Keywords: Cancer, HIV, pharmacogenetics, chemotherapy, polymorphisms
Abstract: Physicians prescribing drugs are routinely confronted with the balance between efficacy and toxicity. Pharmacogenetics involves the study of how inheritance influences response to drugs, and its goal is to enable the appropriate selection of these individuals, thus eliminating unpredictable responses. Pharmacogenetics can be used to identify target populations that either will have minimal benefit or a better outcome including better survival or improvement in surrogate end points. As we move towards common use of targeted therapies, the future of medicine will involve an examination of the interplay between multiple genetic factors, as the response to drugs is likely to be complex and polyfactorial especially in chronic diseases. There has already been some success in situations where single genes play a large role in the overall drug response, and this is discussed with reference to commonly used cytotoxics and antiretrovirals, encompassing the major principles of pharmacogenetics.
Export Options
About this article
Cite this article as:
Winston Alan, Hatzimichael Eleftheria, Marvin Vanessa, Stebbing Justin and Bower Mark, Host Pharmacogenetics in the Treatment of HIV and Cancer, Current Drug Safety 2006; 1 (1) . https://dx.doi.org/10.2174/157488606775252683
DOI https://dx.doi.org/10.2174/157488606775252683 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting the BH3 Domain of Bcl-2 Family Proteins. A Brief History From Natural Products to Foldamers As Promising Cancer Therapeutic Avenues
Current Medicinal Chemistry microRNAs: Innovative Targets for Cerebral Ischemia and Stroke
Current Drug Targets Dual Targeting of Glioma U251 Cells with Nanoparticles Prevents Tumor Angiogenesis and Inhibits Tumor Growth
Current Neurovascular Research Nanotheranostics: The Fabrication of Theranostics with Nanoparticles and their Application to Treat the Neurological Disorders
Recent Patents on Nanotechnology Brain Cancer-Activated Microglia: A Potential Role for Sphingolipids
Current Medicinal Chemistry Molecular Imaging of Breast Cancer: Role of RGD Peptides
Mini-Reviews in Medicinal Chemistry The Kynurenine Pathway in the Acute and Chronic Phases of Cerebral Ischemia
Current Pharmaceutical Design Targeting 5-Lipoxygenase for Prevention and Treatment of Cancer
Current Enzyme Inhibition Therapeutic Application of Histone Deacetylase Inhibitors for Stroke
Central Nervous System Agents in Medicinal Chemistry The ‘Other’ Telomerase Inhibitors: Non-G-Quadruplex Interactive Agent, Non-Antisense, Non-Reverse Transcriptase Telomerase Inhibitors
Current Medicinal Chemistry - Anti-Cancer Agents Novel Natural and Synthetic Ligands of the Endocannabinoid System
Current Medicinal Chemistry Nanotechnology-enabled Chemodynamic Therapy and Immunotherapy
Current Cancer Drug Targets Recent Advances in Delivery Through the Blood-Brain Barrier
Current Topics in Medicinal Chemistry CD36-TSP-HRGP Interactions in the Regulation of Angiogenesis
Current Pharmaceutical Design The Intriguing Interplay Between Therapies Targeting the Epidermal Growth Factor Receptor, the Hypoxic Microenvironment and Hypoxia-inducible Factors
Current Pharmaceutical Design Age and Dose-Dependent Effects of Alpha-Lipoic Acid on Human Microtubule- Associated Protein Tau-Induced Endoplasmic Reticulum Unfolded Protein Response: Implications for Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Cellular Iron Homeostasis and Therapeutic Implications of Iron Chelators in Cancer
Current Pharmaceutical Biotechnology Poly(Ethylene Glycol) Amphiphilic Copolymer for Anticancer Drugs Delivery
Anti-Cancer Agents in Medicinal Chemistry Stem Cells as Vectors to Deliver HSV/tk Gene Therapy for Malignant Gliomas
Current Stem Cell Research & Therapy Salinomycin: A Novel Anti-Cancer Agent with Known Anti-Coccidial Activities
Current Medicinal Chemistry